rheumatism, rheumatoid arthritis rheumatism
Conditions
Interventions
A tapering decision aid based on a dynamic flare prediction model in addition
to disease-activity-guided dose optimisation (DGDO) in regular patient care.
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • A clinical diagnosis of rheumatoid arthritis as assessed by the treating rheumatologist. It will be registered if patients meet ACR 1987 or EULAR/ACR 2010 criteria. If these criteria are not met, the separate components of the criteria will be registered. • Treatment of their RA with one of the following bDMARDs that are registered for RA in >=66% of the standard dose (i.e. maximally one dose reduction step previously taken): adalimumab, certolizumab, golimumab, infliximab, etanercept, sarilumab, tocilizumab or abatacept). • Patient is eligible to taper bDMARD according to treating physician (i.e. no other indication for bDMARD such as psoriasis or IBD, i.e. no recent relevant radiographic progression). • Stable low disease activity with current bDMARD for >= 6 months according to treating physician • Current DAS28-CRP
Exclusion criteria
Exclusion criteria: • Recent earlier (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: the number of flares per patient over 18 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Main secondary endpoint: dose reduction (expressed as percentage of full-dose) over 18 months. | — |
Countries
Netherlands
Contacts
Public ContactP.M.J. Welsing
Universitair Medisch Centrum Utrecht
Outcome results
None listed